化学
药物发现
计算生物学
药品
药物开发
小分子
药理学
组合化学
生物化学
医学
生物
作者
Andrew C. Flick,Carolyn A. Leverett,Hong X. Ding,Emma L. McInturff,Sarah Fink,Subham Mahapatra,Daniel W. Carney,Erick A. Lindsey,Jacob C. DeForest,Scott P. France,Simon Berritt,Simone V Bigi-Botterill,Tony Gibson,Rebecca B. Watson,Yiyang Liu,Christopher J O’Donnell
标识
DOI:10.1021/acs.jmedchem.2c00710
摘要
New drugs introduced to the market are privileged structures that have affinities for biological targets implicated in human diseases and conditions. These new chemical entities (NCEs), particularly small molecules and antibody-drug conjugates (ADCs), provide insight into molecular recognition and simultaneously function as leads for the design of future medicines. This Review is part of a continuing series presenting the most likely process-scale synthetic approaches to 44 new chemical entities approved for the first time anywhere in the world during 2020.
科研通智能强力驱动
Strongly Powered by AbleSci AI